We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
基于网络药理学和分子对接技术的化滞柔肝颗粒治疗非酒精性脂肪性肝病的作用机制研究.
- Authors
刘莹莹; 张景媛; 谭影影; 王郝嘉; 伍 超; 范啸天; 李佳霖; 陈美琳; 吴嘉瑞
- Abstract
OBJECTIVE: To probe into the potential mechanism of Huazhi Rougan Granules in the treatment of non-alcoholic fatty liver disease(NAFLD) based on network pharmacology and molecular docking. METHODS: The drug compound targets were screened by using the Traditional Chinese Medicine Systematic Pharmacology Database and Analysis Platform and the Encyclopedia of Chinese Medicine database, the disease targets of NAFLD were screened by using the GeneCards database and DigSee database, so that the related networks were constructed. Gene ontology function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed for the shared targets by using R language. Finally, the molecular docking verification of key compounds and core targets was conducted, and the results were visualized by using Pymol software. RESULTS: The predicted core compounds were quercetin, kaempferol, luteolin and wogonin, the core targets were signal transduction and activating transcription factor 3, JUN, interleukin-6, tumor necrosis factor, CXCL8, vascular endothelial growth factor A, epidermal growth factor, interleukin-1β, chemokine ligand 2 and TP53. The results of KEGG pathway enrichment analysis showed that the pathways were associated with infectious diseases, immune system, endocrine and metabolic diseases, such as the AGE-RAGE signaling pathway, human cytomegalovirus infection and other signaling pathways in diabetic complications. CONCLUSIONS: The results of this study have initially validated and predicted the mechanism of Huazhi Rougan granules in the treatment of NAFLD, which laid a good foundation for further insight into its mechanism of action.
- Subjects
NON-alcoholic fatty liver disease; VASCULAR endothelial growth factors; EPIDERMAL growth factor; HUMAN cytomegalovirus diseases; TUMOR necrosis factors; TRANSGENIC organisms
- Publication
Evaluation & Analysis of Drug-Use in Hospitals of China, 2022, Vol 22, Issue 4, p395
- ISSN
1672-2124
- Publication type
Article
- DOI
10.14009/j.issn.1672-2124.2022.04.003